BTAI
BioXcel Therapeutics Inc
Halal Rating :
Last Price
$0.34
Last updated:
Market Cap
-
7D Change
-10.94%
1 Year Change
-86.9%
Company Overview
Industries
Exchange
Next Earnings Date
BioXcel Therapeutics is a biopharmaceutical company focused on developing artificial intelligence-enabled neuroscience and immuno-oncology medicines. Their lead product, IGALMI (dexmedetomidine) sublingual film, is FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $214000.0 | $19.3m | - | $3.79m | 0.00% | 19.64% |
| June 30, 2024 | $1.1m | $22.1m | - | $3.7m | 0.00% | 16.74% |
| March 31, 2024 | $582000.0 | $28.35m | - | $3.61m | 0.00% | 12.72% |
Company Impact
Help us evaluate BioXcel Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.